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Abstract
Background: We evaluated the predictive value of IGF-1 against hGH in the treatment outcome. 
Material and methods: A prospective study was undertaken of 47 patients (mean age 41.1 ± 12.9 years; 44 with macroadenoma and 
3 with microadenoma), requiring treatment with octreotide LAR (SSLAR) following incomplete surgery. Concentrations of hGH and IGF-1 
were measured three months after surgery and three, six, nine, 12, 18, and 24 months after introducing SSLAR. 
Results: Following surgery, respective median values of hGH and IGF-1 concentrations were 5.55 ng/mL (IQR = 7.1) and 512.7 ng/mL 
(IQR = 379.5). After six, 12, and 24 months of SSLAR treatment, median values of hGH decreased significantly: to 2.95 ng/mL (IQR = 5.5, 
p < 0.05), 2.95 ng/mL (IQR = 4.4, p < 0.05) and 2.00 ng/mL (IQR = 3.6, p < 0.001), respectively. 
After six, 12, and 24 months of SSLAR treatment, the respective median IGF-1 concentrations significantly decreased to 384.5 ng/mL 
(IQR = 312.2, p < 0.01), 323.0 ng/mL (IQR = 230.3, p < 0.001) and 334.0 ng/mL (IQR = 328.9, p < 0.01). The differences between median 
hGH and IGF-1 concentrations at 12 and 24 months were not significant. A statistically significant correlation was found between IGF-1 
concentration prior to and after surgery (R = 0.61, p < 0.05) and prior to SSLAR treatment and IGF-1 concentration 24 months later 
(R = 0.49, p < 0.05). No such correlation was observed for hGH. 
Conclusions: The level of IGF-1 prior to surgery and prior to SSLAR treatment is a better predictor of the treatment outcome than hGH. Octreotide 
LAR was most effective over the first 12 months of treatment. No further significant decrease of hGH or IGF-1 levels was observed past this period. 
(Pol J Endocrinol 2011; 62 (5): 401–408)
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Streszczenie
Wstęp: Porównano wartość predykcyjną stężenia IGF-1 oraz hGH w ocenie wyników leczenia akromegalii. 
Materiał i metody: W prospektywnym badaniu wzięło udział 47 pacjentów (średnia wieku 41,1 ± 12,9 roku, 44 z makrogruczolakiem 
i 3 z mikrogruczolakiem przysadki), u których konieczne było zastosowanie leczenia oktreotydem LAR (SSLAR) po nieskutecznej operacji. 
Stężenia hGH i IGF-1 mierzono 3 miesiące po operacji oraz 3, 6, 9, 12, 18 i 24 miesiące po włączeniu leczenia SSLAR. 
Wyniki: Stężenie hGH i IGF-1 po operacji wynosiło odpowiednio: 5,55 ng/mL (IQR = 7,1) i 512,7 ng/mL (IQR = 379,5). 
Po 6, 12 i 24 miesiącach terapii SSLAR mediany stężenia hGH obniżyły się znamiennie do wartości odpowiednio: 2,95 ng/mL (IQR = 5,5, 
p < 0,05), 2,95 ng/mL (IQR = 4,4, p < 0,05) oraz 2,00 ng/mL (IQR = 3,6, p < 0,001). Po 6, 12 i 24 miesiącach leczenia SSLAR mediany stężenia 
IGF-1 obniżyły się znamiennie do wartości odpowiednio: 384,5 ng/mL (IQR = 312,2, p < 0,01), 323,0 ng/mL (IQR = 230,3, p < 0,001) oraz 
334,0 ng/mL (IQR = 328,9, p < 0,01). Mediany stężenia hGH oraz IGF-1 po 12 i 24 miesiącach leczenia nie różniły się istotnie. 
Stwierdzono znamienną korelację pomiędzy stężeniem IGF-1 przed operacją i po niej (R = 0,61, p < 0,05) oraz pomiędzy IGF-1 przed 
leczeniem SSLAR i po 24 miesiącach terapii (R = 0,49, p < 0,05). Nie obserwowano takiej zależności dla hGH. 
Wnioski: Stężenie IGF-1 przed operacją i przed leczeniem SSLAR ma większą wartość predykcyjną wyniku leczenia niż stężenie hGH. 
Oktreotyd LAR był najskuteczniejszy w ciągu pierwszych 12 miesięcy terapii. Nie obserwowano dalszego znamiennego obniżenia stężenia 
hGH i IGF-1. (Endokrynol Pol 2011; 62 (5): 401–408)
Słowa kluczowe: akromegalia, analogi somatostatyny, oktreotyd, przysadka, hormon wzrostu, insulinopodobny czynnik wzrostu-1
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Introduction
The prevalence of acromegaly is generally estimated 
at 50–70 cases per million, while its incidence is about 
3–4 cases per million inhabitants per year [1]. Thus, in 
Poland about 2,000 patients with acromegaly are to be 
expected. Due to slow tumour growth and insidious 
progression of the characteristic features of this di-
sease, diagnosis may be delayed by up to ten years. The 
mortality of patients with uncontrolled acromegaly is 
considerably higher than that in normal populations, 
the standardised mortality ratio being 1.72 [2]. The life 
span of acromegaly patients is some ten years shorter 
than that of the general population [3]. The most com-
mon causes of death are cardiovascular, with 2–3 fold 
higher mortality than that of the general population 
[4–7]. Cerebrovascular [8, 9], respiratory and metabolic 
complications are also seen in these patients [10–13].
The prognostic factors which determine the course 
of acromegaly are permanently elevated concentra-
tions of hGH (human growth hormone) and IGF-1 
(insulin-like growth factor-1), patient age, size and 
invasiveness of tumour mass, as well as duration of 
symptoms and signs of disease [14].
Considering the relationship between hGH concen-
tration and patient mortality, maintaining levels of hGH 
below 2.5 ng/mL in acromegaly patients resulted in their 
mortality approaching that of the general population 
[2, 4, 8]. Hence, this level for evaluating the outcome of 
surgery was approved at Cortina in the year 2000 [15]. 
However, Holdaway et al. [16] demonstrated that a better 
outcome could be achieved if levels of hGH < 1 ng/mL 
were maintained. This value was accepted in 2009 by the 
Acromegaly Consensus Group in Paris [17].
Treatment of acromegalic patients with somatostatin 
analogues decreases hGH and IGF-1 concentrations, 
improves their general and metabolic condition, and 
decreases morbidity and mortality. In postoperative 
follow-up, normalised IGF-1 concentration was strongly 
associated with lower prevalence of impaired glucose 
tolerance and lower diastolic blood pressure [18]. 
In our prospective uncontrolled and non-ran-
domised study of the treatment outcome, we evaluated 
the predictive value of the level of IGF-1 prior to surgery 
and prior to octreotide LAR (SSLAR) treatment follow-
ing incomplete surgery of pituitary adenoma, against 
the level of hGH.
Material and methods
We followed 85 acromegaly patients who underwent 
transsphenoidal surgery without SSLAR pre-treatment. 
Lack of such pre-treatment was due to limited availabil-
ity of SSLAR in Poland in the early years of this study. 
The presently applied standards of the Polish Endocrine 
Society, i.e. 6–12 months of treatment with somatostatin 
analogues (SSA) prior to surgery, were adopted in 2007 
[19].Of all 85 patients operated upon, 80% (68 patients) 
presented with macroadenoma and 20% (17 patients) 
with microadenoma. In all 85 patients the pituitary 
function was evaluated prior to and three months after 
surgery [20, 21]. Patients with impaired anterior pitui-
tary function and/or diabetes insipidus received appro-
priate treatment. As based on the Cortina criteria [15], 
radical cure was achieved in 38 patients, i.e. in 44.7% 
of all patients operated upon. In the macroadenoma 
group, radical cure was achieved in 24/68 patients, i.e. 
in 35.3% of these patients operated, as compared to the 
microadenoma group in which 14/17 patients, i.e. 82.4%, 
were successfully operated. 
A total of 47 patients (mean age 41.1 ± 12.9 years, 
29 female and 18 male, 44 patients presenting with 
macroadenoma and 3 with microadenoma) required 
further treatment with SSLAR due to incomplete sur-
gery. Three months after surgery, they had not fulfilled 
the cure criteria (basal hGH < 2.5 ng/ml, IGF-1 within 
normal range for age and sex and and no inhibition of 
hGH < 1.0 ng/mL in the 120th min of the OGTT). Eighteen 
patients who underwent pituitary surgery prior to the 
availability of somatostatin analogues in Poland in 2004 
were re-evaluated before commencing their SSLAR treat-
ment (13 patients were qualified). The mean time of active 
disease duration prior to diagnosis was 8.1 ± 6.1 years. 
The efficacy of treatment was evaluated by mea-
suring concentrations of fasting hGH and IGF-1 prior 
to SSLAR treatment and repeated three, six, nine, 12, 
18 and 24 months later. The dose of Sandostatin LAR 
was 20 mg/month, increased to 30 mg/month if an un-
satisfactory response was observed, or decreased to 
10 mg/month if satisfactory biochemical control was 
achieved over at least three consecutive months.
Serum hGH concentrations were measured using 
the IRMA method (Immunotech) with a detection limit 
of 0.03 ng/mL (WHO IS 98/574). Serum IGF-1 concen-
trations were determined using RIA (DiaSource) with 
a detection limit of 3.4 ng/mL (NIBSC 1st IRR 87/518). 
This study was approved by the Ethical Committee 
of the Jagiellonian University (approval 154/B/2005). 
Written informed consent was obtained from all pa-
tients on their admission to hospital to approve their 
diagnostic and treatment procedures, follow-up and 
to compile their medical data into a research database. 
Statistical analysis
Data analysis was performed using Statistica version 
9.0 software. The Shapiro-Wilk test was applied to 
analyse distributions of data. As the data was found 
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not to be normally distributed, non-parametric tests 
were applied. Two-tailed tests were used throughout. 
Median values and inter-quartile ranges (IQR) of hGH 
and IGF-1 concentrations are therefore given. For paired 
data the Wilcoxon rank sum test, and for unpaired data 
the Mann-Whitney U test, were applied. Fisher’s exact 
test and ANOVA Friedman test were used to evaluate 
the efficacy of SSLAR treatment over the given time 
periods. In longitudinal studies, we assumed that the 
intermittent missing observations were random [22]. 
In all 47 patients, baseline values of hGH and IGF-1 
prior to pituitary surgery and prior to SSLAR treatment 
were established. As the number of missing values at 
each time point differed across the observation, the 
available number of patients is given as the value of n, 
along with the value of p. P < 0.05 was considered to 
be statistically significant.
Results
In 47 patients (55.3% of all patients operated upon) who 
required further treatment with SSLAR, the median val-
ues of hGH before and after surgery were 24.23 ng/mL 
(IQR = 35.8) and 5.55 ng/mL (IQR = 7.1), respectively, 
the difference being statistically significant (p < 0.0001, 
n = 47) (Figure 1). Respective median values of IGF-1 be-
fore and after surgery were 1,018.0 ng/mL (IQR = 433.9) 
and 512.7 ng/mL (IQR = 379.5), (p < 0.001, n = 47) 
(Figure 1). Median values of hGH in the 120th min of 
the OGTT before and after surgery were 11.3 ng/mL 
(IQR = 33.3) and 3.6 ng/mL (IQR = 1.8) respectively, the 
difference being statistically significant, p < 0.05, n = 47. 
No significant correlation was found between 
maximum tumour diameter (median value 18 mm; 
min = 9 mm, max = 60 mm) and hGH or IGF-1 con-
centrations prior to surgery (p > 0.05, n = 47), nor was 
any significant correlation found between maximum 
tumour diameter and hGH or IGF-1 levels after surgery 
(p > 0.05, n = 47). 
A significant correlation was found between IGF-1 
serum concentration before and after surgery (Spear-
man correlation coefficient R = 0.61, p < 0.05, n = 47). 
No such correlation was found (p > 0.05) with respect to 
serum concentration of hGH prior to and after surgery. 
Based on ANOVA Friedman test, a significant decrease 
in hGH (p < 0.05, n = 26) and IGF-1 (p < 0.05, n = 25) con-
centrations was stated over the time of SSLAR treatment. 
After six, 12, and 24 months of SSLAR treatment, me-
dian values of hGH decreased significantly, compared 
to hGH levels before SSLAR treatment: to 2.95 ng/mL 
(IQR = 5.5, p < 0.05, n = 32), 2.95 ng/mL (IQR = 4.4, 
p < 0.05, n = 32) and 2.00 ng/mL (IQR = 3.6, p < 0.001, 
n = 28), respectively, as based on Wilcoxon rank sum 
matched-pairs test (Figure 2). The differences between 
median hGH concentrations at 12 and 24 months were 
not statistically significant (p > 0.05, n = 28) (Figure 2). 
After 24 months of SSLAR treatment, the median hGH 
concentration value decreased by a factor of 2.8. 
After six, 12, and 24 months of SSLAR treatment, 
respective median IGF-1 levels also significantly 
decreased as compared to those before SSLAR treat-
ment: 384.5 ng/mL (IQR = 312.2, p < 0.01, n = 28), 
323.0 ng/mL (IQR = 230.3, p < 0.001, n = 31) and 334.0 
ng/mL (IQR = 328.9, p < 0.01, n = 28) (Figure 3). The 
Figure 1. Median values of hGH and IGF-1 concentration in acromegalic patients prior to and following unsuccessful surgery 
of pituitary adenoma (n = 47)
Rycina 1. Mediany stężenia hGH i IGF-1 przed i po nieskutecznej operacji gruczolaka przysadki u pacjentów z akromegalią (n = 47)
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differences between median IGF-1 concentrations at 12 
and 24 months were not significant (p > 0.05, n = 28) (Fi-
gure 3). After 24 months of SSLAR treatment, the median 
IGF-1 concentration value decreased by a factor of 1.5. 
Prior to their SSLAR therapy, the median value of 
IGF-1 was 464.1 ng/mL (IQR = 289.4, n = 16) in the 
group of patients who achieved normal IGF-1 concen-
tration after 24 months of treatment, and 744.0 ng/mL 
(IQR = 420.5, n = 11) in the group who did not, the dif-
ference being statistically significant (U Mann-Whitney 
test, p < 0.05) (Figure 4). The median values of hGH 
prior to SSLAR treatment in the group who achieved 
Figure 2. Median values of hGH concentration in acromegalic patients treated with SSLAR following unsuccessful surgery 
— a 24 month observation (n = 47)
Rycina 2. Mediany stężenia hGH u pacjentów z akromegalią leczonych SSLAR po nieskutecznej operacji – obserwacja 24-miesięczna 
(n = 47)
Figure 3. Median values of IGF-1 concentration in acromegalic patients treated with SSLAR following unsuccessful surgery 
— a 24 month observation (n = 47)
Rycina 3. Mediany stężenia IGF-1 u pacjentów z akromegalią leczonych SSLAR po nieskutecznej operacji — obserwacja 24-miesięczna 
(n = 47)
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hGH < 2.5 ng/mL after 24 months of therapy and in 
the group who did not were 4.2 ng/mL (IQR = 5.5, 
n = 16) and 5.7 ng/mL (IQR = 5.0, n = 11), respectively 
(p > 0.05) (Figure 4).
Significant correlation was found between IGF-1 
concentration before SSLAR treatment and IGF-1 
concentration 24 months later, at the end of this ob-
servation (Spearman coefficient R = 0.49, p < 0.05, 
n = 28). No such correlation was observed for hGH 
after 24 months. 
After six months of SSLAR treatment, hGH < 2.5 ng/mL 
and IGF-1 normalisation were achieved in 33.3% (10/30) 
and 42.3% (11/26) of patients, respectively. After 
24 months of SSLAR treatment, hGH < 2.5 ng/mL and 
IGF-1 normalisation for age and gender were achieved 
in 60.7% (17/28) and 57.1% (16/28) of patients, respec-
tively. After six and 24 months, normalisation of both 
parameters was achieved in 22.7% (5/22) and 40.0% 
(10/25) of patients, respectively (Figure 5). It also fol-
lows from Figure 5 that the percentage of patients who 
achieved normal IGF-1 after 12 months of treatment 
remained practically the same over the next 12 months 
of observation (54.8% vs. 57.1%), while the percentage 
of patients in whom hGH concentration did not exceed 
2.5 ng/ml, increased (45.2% vs. 60.7%). However, based 
on exact Fisher test, these differences were not found 
to be statistically significant (p > 0.05). 
Discussion
As active acromegaly typically remains undiagnosed 
for several years, the long-term effect of high concen-
trations of hGH and IGF-1 may result in the develop-
ment of complications, such as cardiovascular [4–7], 
cerebrovascular [8, 9], respiratory or metabolic [10–13], 
or neoplastic [23]. Early diagnosis, cessation of hGH 
hypersecretion and normalisation of IGF-1 secretion 
are the main goals of acromegaly treatment, since 
biochemical control of the disease decreases morbid-
ity and normalises the mortality rate in these patients 
[7, 16]. In our group of patients, the period of active 
disease was estimated at 8–14 years, with a high per-
centage of macroadenomas at the time of diagnosis, 
especially in patients with incomplete pituitary sur-
gery (44/47 patients, 93.6%), compared to 70–73% in 
other studies [24–26]. 
While transsphenoidal selective tumour resection 
remains the treatment of choice [15, 27, 28], the efficacy 
of primary medical treatment using somatostatin ana-
logues is currently under review [28–30]. For patients in 
whom surgery is unsuccessful, long-acting somatostatin 
analogues, presently octreotide or lanreotide, or pegviso-
mant, a hGH receptor antagonist, or combination treat-
ments, are recommended [30–32]. The efficacy of surgery, 
which depends on the tumour size, on its location, and on 
Figure 4. Median values of hGH and IGF-1 concentrations in acromegalic patients prior to SSLAR treatment. A — patients who 
achieved the level of hGH < 2.5 ng/mL after 24 months of SSLAR treatment. B — patients with the level of hGH > 2.5 ng/mL after 
24 months of SSLAR treatment. C — patients who achieved the level of IGF-1 within normal range for age and gender after 24 months 
of SSLAR treatment. D — patients with the level of IGF-1 above normal range for age and gender after 24 months of SSLAR treatment.
Rycina 4. Mediany stężenia hGH i IGF-1 u pacjentów z akromegalią przed leczeniem SSLAR. A — pacjenci, którzy osiągnęli stężenie 
hGH < 2,5 ng/mL po 24 miesiącach leczenia SSLAR. B — pacjenci, których stężenie hGH wynosiło > 2,5 ng/mL po 24 miesiącach 
leczenia SSLAR. C — pacjenci, którzy osiągnęli stężenie IGF-1 w normie dla wieku i płci po 24 miesiącach leczenia SSLAR. D — pacjenci 
ze stężeniem IGF-1 powyżej normy dla wieku i płci po 24 miesiącach leczenia SSLAR
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the baseline hGH level, is 61–91% in the case of microad-
enoma and 23–53% for macroadenoma [20, 21, 24, 33–35]. 
In our group of 85 patients who underwent surgery, 
cure was achieved in 35.3% of macroadenoma patients 
compared to 82.4% of microadenoma patients. Thus, in 
most of our patients, the disease persisted after surgery, 
requiring further treatment. 
In the 47 patients in whom surgery was incomplete, 
no correlation was found between maximum tumour 
diameter and hGH or IGF-1 concentration prior to 
surgery, nor was any correlation found between maxi-
mum tumour diameter and hGH or IGF-1 concentra-
tion after surgery. Krzentowska-Korek et al. [20] found 
a correlation between basal serum hGH concentration 
and tumour size. Rieger et al. [36] reported that high 
hGH levels prior to and after surgery correlated better 
than IGF-1 with tumour size and invasiveness. Perhaps 
due to the high incidence of macroadenoma (over 90% 
of patients) with concomitant high serum hGH and 
IGF-1 concentrations, such a correlation was missing 
in our study. Under these circumstances, the efficacy of 
surgery, as based on hGH and IGF-1 concentration, is 
perhaps biased by tumour location, invasiveness, and 
the surgeon’s experience [37]. 
While a positive correlation was found between 
IGF-1 concentration prior to and after surgery, no such 
correlation was found for hGH. Thus, in our study 
group, higher IGF-1 concentration prior to surgery 
indicated a poorer chance of acromegaly control by 
surgery alone. Indeed, Besser et al. [35] found several 
other predictors of acromegaly resistant to treatment 
i.e. large tumour size and high hGH secretion which 
were also present in our patients. 
In our group of 47 acromegaly patients after incom-
plete pituitary adenoma surgery treated with SSLAR over 
24 months, decreases in hGH and IGF-1 concentrations 
were observed. The median value of hGH concentration 
decreased from the initial 5.55 ng/mL to 2.0 ng/mL (a 64% 
decrease). After 24 months of treatment, the median value 
of IGF-1 concentration decreased from 512.7 ng/mL to 
334.0 ng/mL (a 35% decrease). 
We note consistency between our results and those 
of the retrospective study by Colao et al. [38]. In their 
study of the efficacy of postsurgical SSLAR treatment 
over a 12-month median observation time, a 40–80% 
decrease of hGH concentration depending on tumour 
size was observed, as was a 30–40% decrease of IGF-1 
concentration from baseline over the same period. In 
a similar lanreotide post-surgery efficacy study, a de-
crease of 38% in mean hGH and IGF-1 concentrations 
from baseline values was found after 36 months of 
treatment [39]. 
In our group of patients, differences between the 
median concentrations of hGH or IGF-1 after 12 and 
24 months of treatment were not significant. We there-
fore conclude that somatostatin analogues provide 
effective post-surgery therapy in acromegaly patients, 
and that the degree of disease control achievable within 
the first year of treatment is most important. While 
Maiza et al. [25] observed continuous decreases in hGH 
and IGF-1 over ten years of primary treatment with dif-
ferent SSA, Ayuk et al. [40] found no difference between 
hGH and IGF-1 concentrations after 24 and 48 weeks of 
Sandostatin LAR treatment in a group of 57 patients. We 
support the results of Ayuk et al. [40]. 
In the studied group of patients in whom surgery 
was not effective, we evaluated factors which could 
affect the efficacy of octreotide LAR treatment after 
24 months. The baseline level of IGF-1 prior to SSLAR 
treatment was found to be an important indicator of the 
Figure 5. Percentage of patients who achieved serum concentration of hGH < 2.5 ng/mL and IGF-1 concentration within normal range 
for age and gender in the course of SSLAR treatment following unsuccessful surgery (n = 47)
Rycina 5. Procent pacjentów, którzy osiągnęli stężenie hGH < 2,5 ng/mL i IGF-1 w normie dla wieku i płci w trakcie leczenia SSLAR 
po nieskutecznej operacji (n = 47)
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final outcome of the 24-month treatment. Namely, in 
those patients in whom IGF-1 did not normalise for age 
and gender, the baseline level of IGF-1 was higher than 
that in patients in whom SSLAR was effective. No such 
relationship was observed with respect to the levels of 
hGH. Recently, Melmed et al. [41] have shown that less 
severe acromegaly at baseline can be controlled by low 
doses of lanreotide Autogel, although not all studies of 
somatostatin analogues agree with this observation [42]. 
While in our study, a positive correlation was found 
between IGF-1 concentration prior to SSLAR treatment 
and after 24 months, no such correlation was observed 
with respect to hGH. This suggests that the baseline 
level of IGF-1 may be more useful than hGH in predict-
ing the outcome of SSLAR treatment. It would thus 
appear that IGF-1 is a more reliable marker, albeit not 
exclusively, in defining remission or cure [43]. Brabant 
et al. [44] demonstrated that serum concentration of 
IGF-1 correlates with clinical and biochemical features 
of acromegaly. It seems that IGF-1 is a more sensi-
tive indicator of persistent disease activity than hGH 
[26, 43, 45], as the level of hGH is related to the remain-
ing tumour mass, while the level of IGF-1 is related to 
the activity of hGH secreted by this mass. 
Normalisation of both hGH and IGF-1 was achieved 
in 40% of our patients, in comparison with 38% achieved 
in a study of efficacy of lanreotide Autogel over 48 weeks 
by Chanson et al. [26] and with 43%, over 52 weeks, by 
Melmed et al. [41]. In a meta-analysis by Freda et al. 
[46], 56% and 66% of patients treated with SSLAR 
achieved cure criteria for hGH and IGF-1 respectively, 
although different observation periods were quoted 
and compared within this meta-analysis. In our study 
group, after 24 months of SSLAR treatment, levels of 
hGH < 2.5 ng/mL or IGF-1 normal for age and gender 
were achieved by 60.7% and 57.1% of patients, respective-
ly. Calao et al. reported a decrease of hGH < 2.5 ng/mL 
in 56% of patients and normalised IGF-1 in 55% of their 
patients after a median 12 months of treatment [38]. In 
a recent randomised study of lanreotide Autogel, Melmed 
et al. [41] reported a decrease of hGH < 2.5 ng/mL in 54% 
of patients and normalised IGF-1 in 59% of patients after 
52 weeks of treatment, as compared with our 45% and 
55%, respectively, over the same period.
Conclusions
 — We found the level of IGF-1 prior to surgery and 
prior to SSLAR treatment to be a better predictor of 
treatment outcome than the level of hGH. 
 — We found octreotide LAR to be most effective over 
the first 12 months of treatment. After that period, we 
have not observed any further significant decrease 
in hGH or IGF-1 levels up to two years of treatment. 
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